Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated preliminary efficacy and ...

An investigational anticoagulant that targets factor XI failed to prevent arteriovenous graft (AVG) thrombosis in chronic hemodialysis patients ... for the 6-mg group (HR 0.93, 95% CI 0.52-1. ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

All forms of medical services at the National Institute of Ophthalmology and Hospital in Dhaka remained suspended for the ...

which is designed to assess its potential benefit in early breast cancer patients with high risk of recurrence." In addition, the company will be presenting other data at the ASCO Annual Meeting.

Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three ...

“We have convened a meeting of all departmental heads. The patients who died on Tuesday (June 3, 2025) night were admitted to the hospital in a critical condition. Prima facie, the deaths seem ...

With the benefits rivaling some drugs, experts said cancer centers and insurance plans should consider making exercise ...